Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

101205 shape aha 2005 f

131 views

Published on

SHAPE Society

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

101205 shape aha 2005 f

  1. 1. Zahi A. Fayad, PhD Associate Professor Imaging Science Laboratories Depts of Radiology and Medicine The Zena and Michael A. Wiener Cardiovascular Institute and The Marie-Josee and Henry R. Kravis Cardiovascular Health Center Mount Sinai School of Medicine, New York, NY 11-12-2005 AEHA - Shape Guidelines Dallas, Tx Noninvasive Molecular Imaging of Atherosclerosis With MRI - The Future Lies in Molecular Imaging, The question is which molecule
  2. 2. Choudhury RP; Fuster V; Fayad ZA Nature Drug Dev. 2004;3:913-925 Atherosclerosis: A Progressive Process Imaging Science Laboratories
  3. 3. Noninvasive Detection of Plaque Instability with Use of Radiolabeled (SPECT) Annexin A5 in Patients with Carotid-Artery Atherosclerosis Kietselaer BLJH et al. NEJM 350;14;April 1, 2004 •Left-Sided TIA 3 days before imaging •Annexin A5 hot spot •Annexin A5 staining •Right-sided TIA 3 months before imaging ªNo Annexin hot spot •No Annexing A5 staining
  4. 4. Davies JR, Rudd JH, Stroke 2005 in press Plaque Activity Assessment -18F-FDG- Macs PET/CT or PET/MR Rudd JHF et al. Circ 2002;105:2708-2711
  5. 5. • Paramagnetic (Iron) • Superparamagnetic (Gd) • Targeted Contrasts/Carriers Current Contrast-Enhanced MR Limited Plaque Activity Information Gd-chelate enhanced -non specific Targeted enhanced contrast agent - specific interaction with plaque Choudhury RP; Fuster V; Fayad ZA Nature Drug Dev. 2004 Aorta IVC Non specific Targeted
  6. 6. Molecular Imaging Contrast Agents Choudhury RP; Fuster V; Fayad ZA Nature Drug Dev. 2004 Lipinski MJ; Fuster V; Fayad ZA Nature Cardiovascular Medicine 2004 • Improve MR detection sensitivity • CA w high-relaxivity - e.g., small peptides • Increase payload of contrast agent • Targeted/Functional • Colloidal Carriers/Lipid based - Liposomes - microemulsions - micelles - lipoproteins • Targets
  7. 7. Age Characterization Using Fibrin-Targeted MR Contrast Agent in Chronic Thrombus 0 2 4 6 8 10 12 1 * P<0.01 Pre Acute 48 hours 1 week 2 weeks 3 weeks 4 weeks 6 weeks 8 weeks ContrasttoNoiseRatio(CNR) * * * 4 x Acute Thrombus 4 x 1-week-old Thrombus 10 x 8-week-old Thrombus 4 x 6-week-old Thrombus Sirol M; Fayad ZA et al. Atherosclerosis 2005:182:79-85 Sirol M; Fayad ZA et al. Circ 2005;112:1594-1600
  8. 8. MATRIX METALLOPROTEINASES TARGETING - Gd-peptide Approach IHC of atherosclerotic plaque for MMP2 MMP Zymography of aorta of ApoE mouse 40x 40x P947 (Guerbet) short peptide MMPs inhibitor 100 µmol/kg Amirbekian V; Fayad ZA et al. AHA 2005;D220 @ NOV 15 @ 4:45PM Imaging Science Laboratories NER P947 vs. P1135 0 0.5 1 1.5 2 2.5 3 1 2 3 4 5 Time-Point (1= Pre-Contrast;2= 1hr post;3= 2 hrspost;4 = 3hrs post;5= 22 hrspost) NER P947 External Standard P947 control P1135
  9. 9. Lipid-Based Particulates Lipoproteins: Chylo, VLDL, TG, LDL, HDL • Gd, Iron, Fluorescents, etc. • Ab, peptide, etc.
  10. 10. In Vivo Aortic Atherosclerotic Plaque in ApoE-KO Mice Gd Immunomicelles Macrophages scavenger receptor types I&II Murine (CD204) 9.4T TR=500 ms; TE= 8.6 ms 101 µm in plane spatial resolution 500 µm slice thickness Injected - 13.7µmol/kg Mφ A C Amirbekian V; Fayad ZA et al.; AHA 2005;Nov 15;D220 @2pm Imaging Science Laboratories
  11. 11. Sirol M; Fayad ZA et al. Circulation. 2004;109:2890-2896 Sirol M; Fayad ZA et al. AHA 2005 Nov 15 D220 @ 2:45 pm Atherosclerotic Plaques Detected by Gadofluorine-Enhanced In Vivo MRI Imaging Science Laboratories
  12. 12. Gadofluorine M Plaque MR ApoE-KO mouse lesions • Yellow - localization in ECM (tenascin) • No cellular uptake Mφ Lymphocytes Smooth muscle cells mAb (green) Gadofluorine-carbocyanin conjugate (red) DAPI cell nuclei (blue) Sirol M; Fayad ZA et al. AHA 2005 NOV 15 D220;4:30PM 9.4T TR=500 ms; TE= 8.6 ms 101 µm in plane spatial resolution 500 µm slice thickness 100µmol/Kg (gadofluorine M)
  13. 13. Kelly KA, Weissleder R et al. Circ Res. 2005;96:327-336. Multimodal CLIO-Cy5.5-VCAM-1 Peptide (Iron-peptide) TARGETED SUPERPARAMAGNETIC NP Amino-Cross-linked Iron Oxide =Amino-CLIO
  14. 14. In vivo Macrophage Imaging Using Iron Oxide Particles in Atherosclerotic Rabbits GRASP (white spots)T2* GRE (dark spots) 24h POST CONTRAST
  15. 15.  Lipoprotein carrier  Natural Affinity to plaques  Small size (7-12 nm)  Does not trigger immune reactions  Easily reconstituted  Efficient drug carrier Frias JC et al. J. Am. Chem. Soc. 2004 126(50): p. 163-167 HDL Properties
  16. 16. ApoA-I DMPE-NBD (optical) Unesterified Cholesterol Cholesterol Ester Gd-DTPA- DMPE (MRI) Triglyceride Phospholipid r1p = 10.4 mM-1 s-1 (1.5 T, 25 °C) Imaging Science LaboratoriesFrias JC et al. J. Am. Chem. Soc. 2004 126(50): p. 163-167
  17. 17. 119 98 52 37 30 22 apoA-I H D L rH D L + Gd-D T PA -D M PE kDa GdGd-DTPA-DMPE-DTPA-DMPE rr1p1p = 10.4 mM= 10.4 mM-1-1 ss-1-1 (1.5 T, 25(1.5 T, 25 °°C)C) 4-12% SDS-PAGE DPPE-NBD HN O O P O OH O H O O O NO2 N O N 14 14 reconstitutiondelipidation Control N N H O O O P O OH O H O O O N O N O O O O O OO Gd J. C. Frías et al., J. Am. Chem. Soc., 2004, 126, 16316 12 12
  18. 18. 0 10 20 30 40 50 60 0 10 20 30 40 50 60 70 80 Fraction number Abs280nm rHDL-sphe rHDL-disc apoE-KO plasma (x10) incubated HDL VLDL LDL IDL HDL Cholesterol estersTriglycerides Gadolinium complex Phospholipids ApoA-I Reconstituted hollow spherical HDL Reconstituted discoidal HDL Native incubated HDL
  19. 19. Pre-contrast 48 hours post-contrast1 hr post-contrast 24 hr post-contrast ApoE-KO mice; 4.36 mmol/kg @ 9.4-T MRM rHDL-Gd-DTPA-DMPE Frias JC et al. J. Am. Chem. Soc. 2004 126(50): p. 163-167 DAPI srHDL-NBD CD68:RPE Mφ rHDL for Plaque Detection in ApoE KO Mice
  20. 20.  Silvia Aguiar, MD  Gilbert Aguinaldo, MD  Vardan Amirbekian  Lucy Feliciano  JC Frias, PhD  Fabien Hyafil, MD  Vitalii Itskovich, PhD  Alex Leber, MD  Enric Lopez, MD, PhD  Michael Lipinski  Frank Macaluso, RT  NIH/NHLBI R01HL71021; R01HL78667; R43HL71470  Intellectual Property Managed by Mount Sinai  Venkatesh Mani, PhD  Lena Mara  Gabor Mizsei, MS  Dan Samber, MS  Karen Saebo, PhD  Marc Sirol, MD  Cheuk Tang, PhD  Hiraoki Taniguchi, MD  Esad Vucic, MD  Karen Weinshelbaum Imaging Science Laboratories (ISL) Mount Sinai School of Medicine
  21. 21.  Valentin Fuster, MD, PhD  Donald Smith, MD  Jonathan Halperin, MD  Pedro Moreno, MD  K-R Purushothaman, MD  Michael Farkouh, MD  Mary Ann McLaughlin, MD  Jeffrey Olin, MD  Alison Schecter, MD Radiology  Burton Drayer, MD  Zvi Lefkovitz, MD  Bradley Delman, MD  Emil Cohen, MD CVI  Jesse Weinberger, MD  Stanley Tuhrim, MD Neurology  Sanjay Rajagopalan, MD  Javier Sanz, MD  Santo Dellegrottaglie, MD Clinical CMR/CT Mount Sinai School of Medicine Collaborators  Edward A. Fisher, MD, PhD  John Postley, MD  Carlton Boxhill, MD  Lisa Hudgings, MD  Christine Williams, MD  Tom Starc, MD  Sam Gidding, MD  Kevin Williams, MD  Yukihiko Momiyama, MD  Jean-Francois Toussaint, MD, PhD Pathology  John T. Fallon, MD, PhD Pediatrics  Jeff Saland, MD
  22. 22. The following relationships exist related to this presentation: SOME CONTRAST AGENTS DISCUSSED ARE NOT FDA APPROVED Presenter Disclosure Information  NIH/NHLBI R01HL71021; R01HL78667; R43HL71470  Siemens Medical Solutions  Pfizer/GE HealthCare  Guerbet  Schering  Society of Atherosclerosis Imaging (www.SAI.ORG) President  Society of Cardiovascular Magnetic Resonance Board Member  Intellectual Property Managed by Mount Sinai

×